Atamyo Therapeutics Presents Promising Results in the First Patients Treated With Its ATA-200 Gene Therapy in the Clinical Trial Targeting LGMD-R5 Limb-Girdle Muscular Dystrophy

Atamyo Therapeutics has reported promising results from its ATA-200 gene therapy trial for LGMD-R5 limb-girdle muscular dystrophy. Four patients have been treated, showing safety and significant efficacy, including over 90% muscle fiber expression of the therapeutic gene and reduced muscle damage biomarkers. The trial, led by Dr. Barry Byrne at the University of Florida, aims to evaluate the therapy's safety and effectiveness in children aged 6 to 13. Initial results are encouraging, with further data expected in the coming months. Atamyo Therapeutics focuses on innovative gene therapies for rare muscular dystrophies.